Quantcast

Where Will Facebook Be in 5 Years?

Over two years ago, Facebook (NASDAQ:FB) CEO Mark Zuckerberg said that in five years most of the content on the social networking platform (and its most shared content) would be video. At the time, Facebook Live had just gone global and was apparently a pet project of Zuckerberg, so his boast is understandable. It is now 2.5 years […]

Continue Reading ...
  • Better Buy: Gilead Sciences (GILD) vs. Pfizer (PFE)

    This has been a strange year for Pfizer Inc. (NYSE:PFE) and Gilead Sciences, Inc. (NASDAQ:GILD), and investors are right to wonder which stock makes more sense at the moment. Pfizer practically wrote the book on big acquisitions but has recently shifted gears to focus on its own new drug candidates, as its longtime CEO waves goodbye. Pfizer’s moves don’t seem […]

    Continue Reading ...
  • Better Buy: Apple (AAPL) vs IBM (IBM)

    Apple (NASDAQ:AAPL) is still basking in the limelight since reaching a market cap of $1 trillion back in August. The company’s high-end products and services have delighted its customers for decades, and the recent refresh of its iPhone lineup indicates that there’s no slowing down any time soon. Meanwhile, IBM (NYSE:IBM) has been working on transitioning away from its legacy hardware products over the past few […]

    Continue Reading ...
  • Tesla (TSLA) Stock Plummets: What You Need to Know

    Shares of electric-car maker Tesla (NASDAQ:TSLA) were slammed during after-hours trading on Thursday when news broke that the SEC filed a complaint against CEO Elon Musk, stating he made “a series of false and misleading statements” on Twitter last month about the possibility of taking the company private. As of 6:03 p.m. EDT, Tesla stock was down 13.3% in after-hours trading on Thursday. The […]

    Continue Reading ...
  • My Favorite Large-Cap Biotech Stock to Buy Now

    The runaway success of its vision-restoring drug, Eylea, turned Regeneron Pharmaceuticals(NASDAQ:REGN) into one of biotech’s best performing stocks between 2012 to 2015. However, the company has lost luster with investors since then because of an anemic product launch and a slowing in Eylea’s growth as it’s matured. As a result, Regeneron Pharmaceuticals is no longer at the […]

    Continue Reading ...
  • 3 Top Tech Stocks to Buy Right Now

    Investors looking to get the most bang for their buck ultimately will want at least a portion of their portfolios in technology issues, and here’s why: While the broader market, as represented by the S&P 500, has gained an impressive 16% over the past 12 months, the tech-heavy Nasdaq Composite is up nearly 24%. That’s not a […]

    Continue Reading ...
  • 4 reasons to buy this Semiconductor’s latest dip

    Shares of Cypress Semiconductor (NASDAQ:CY) dipped on Sept. 24 after Morgan Stanley lowered its price target from $15 to $13 while maintaining its “underweight” rating on the stock. The firm claims that Cypress’ margins and earnings could contract in 2019 as NOR and NAND memory prices hit a cyclical peak. Investors should take that gloomy forecast with a grain of […]

    Continue Reading ...